title: Dendritic cell-based vaccines in patients with hematological malignancies.
abstract: The epithelial mucin MUC1 is overexpressed on many epithelial malignancies as well as on some B-cell lymphomas and multiple myelomas. In the present study, we described MUC1 expression also on primary AML blasts. To analyze the presentation of MUC1-derived HLA-A2 restricted peptides by primary AML blasts, we induced MUC1-specific cytotoxic T-lymphocytes (CTLs) in vitro using peptide pulsed dendritic cells from HLA-A2+ healthy donors as antigen-presenting cells. These CTLs efficiently lysed primary AML blasts that constitutively expressed both MUC1 and HLA-A2. The specificity of the CTLs was confirmed in a cold target inhibition assay. Our data demonstrate that MUC1-derived peptides are tumor antigens in AML which could potentially be used for immunotherapeutic approaches.
authors.affiliation: University of Tübingen, Medical Center, Dept. of Hematology, Oncology, Immunology, and Rheumatology, Otfried-Müller Str. 10, 72076 Tübingen, Germany. wolfram.brugger@med.uni-tuebingen.de
authors.forename: W
authors.initials: W
authors.lastname: Brugger
authors.forename: A
authors.initials: A
authors.lastname: Schneider
authors.forename: T
authors.initials: T
authors.lastname: Schammann
authors.forename: P
authors.initials: P
authors.lastname: Dill
authors.forename: F
authors.initials: F
authors.lastname: Grünebach
authors.forename: H J
authors.initials: HJ
authors.lastname: Bühring
authors.forename: L
authors.initials: L
authors.lastname: Kanz
authors.forename: P
authors.initials: P
authors.lastname: Brossart
mesh_terms: D000208:Acute Disease; D017951:Antigen Presentation; D000951:Antigens, Neoplasm / Q000096:biosynthesis / Q000737:chemistry / Q000276:immunology*; D001943:Breast Neoplasms / Q000276:immunology / Q000628:therapy; D019496:Cancer Vaccines / Q000276:immunology*; D002277:Carcinoma / Q000276:immunology / Q000628:therapy; D003602:Cytotoxicity, Immunologic; D003713:Dendritic Cells / Q000276:immunology*; D000939:Epitopes / Q000276:immunology; D005260:Female; D015789:HLA-A2 Antigen / Q000096:biosynthesis / Q000276:immunology*; D019337:Hematologic Neoplasms / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007114:Immunization; D016233:Immunotherapy, Active; D007951:Leukemia, Myeloid / Q000276:immunology* / Q000473:pathology; D008297:Male; D018598:Minisatellite Repeats; D018396:Mucin-1 / Q000096:biosynthesis / Q000737:chemistry / Q000276:immunology*; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000737:chemistry / Q000276:immunology*; D018365:Neoplasm, Residual / Q000628:therapy; D014411:Neoplastic Stem Cells / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000276:immunology / Q000628:therapy; D010446:Peptide Fragments / Q000276:immunology*; D021382:Protein Sorting Signals; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014611:Vaccination
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D000939:Epitopes; D015789:HLA-A2 Antigen; D018396:Mucin-1; D009363:Neoplasm Proteins; D010446:Peptide Fragments; D021382:Protein Sorting Signals